Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MYOC | Q99972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9709062 | 0.79 | MME (0.56) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL6918119 | 0.79 | MAPT (0.70) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL8967473 | 0.78 | MEN1 (0.59) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29111851 | 0.77 | KMT2A (0.62) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29111764 | 0.77 | KMT2A (0.62) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29111760 | 0.77 | KMT2A (0.62) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL11712713 | 0.77 | MEN1 (0.58) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL7125574 | 0.76 | KMT2A (0.61) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL10914836 | 0.76 | KMT2A (0.61) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL987822 | 0.76 | KMT2A (0.61) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0514056-A2 | Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | claimed |
| US-4895715-A | Method of treating gynecomastia | SCHERING CORPORATION (US) | 1990-01-23 | — | — | US | claimed |
| EP-1545479-B1 | COMPOSITIONS OF EZETIMIBE AND METHODS FOR THE TREATMENT OF CHOLESTEROL-ASSOCIATED BENIGN AND MALIGNANT TUMORS | KARYKION INC (US) | 2010-10-27 | — | — | EP | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1545479-A4 | COMPOSITIONS OF EZETIMIBE AND METHODS FOR THE TREATMENT OF CHOLESTEROL-ASSOCIATED BENIGN AND MALIGNANT TUMORS | KARYKION INC (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20050288230-A1 | Non-steroidal anti-androgen therapy | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | US | disclosed |
| EP-1545479-A2 | COMPOSITIONS OF EZETIMIBE AND METHODS FOR THE TREATMENT OF CHOLESTEROL-ASSOCIATED BENIGN AND MALIGNANT TUMORS | Karykion Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004010948-A2 | COMPOSITIONS OF EZETIMIBE AND METHODS FOR THE TREATMENT OF CHOLESTEROL-ASSOCIATED BENIGN AND MALIGNANT TUMORS | KARYKION INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5843953-A | 7-substituted 4-aza cholanic acid derivatives and their use | MERCK & CO., INC. (US) | 1998-12-01 | — | — | US | disclosed |
| US-5693810-A | ENZYME INHIBITORS OF TESTOSTERONE-5ALPHA-REDUCTASE TO PREVENT OR LESSEN SYMPTOMS OF DIHYDROTESTOSTERONE-RELATED HYPERANDROGENIC CONDITIONS, E.G. PROSTATE PROBLEMS, SKIN DISORDERS | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0641208-A4 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-08-30 | — | — | EP | disclosed |
| EP-0641208-A1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023048-A1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0514056-A2 | Use of estrogens or antiandrogens for reversal of male sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4895715-A | Method of treating gynecomastia | SCHERING CORPORATION (US) | 1990-01-23 | — | — | US | disclosed |
| WO-1989000165-A1 | ORALLY ACTIVE ANTIANDROGENS | SCHERING CORPORATION (US) | 1989-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288230-A1 | Non-steroidal anti-androgen therapy | NR5A1, AR, SHBG | MEN1 2418/4885KMT2A 779/4885MAPT 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.